Finding Cures for Tropical Diseases: Putting Innovation Economics to Work Stephen M. Maurer Goldman School of Public Policy Nov. 21, 2006 Economics of.

Slides:

Advertisements

Similar presentations

Thinking About Bioshield Stephen M. Maurer Information & Homeland Security Project UC Berkeley/Goldman School of Public Policy IGCC/AAAS.

Advertisements

1 September 2, 2011 Secretary Ministry of Economic Affairs ECONOMIC DEVELOPMENT POLICY, FOREIGN DIRECT INVESTMENT AND PRIVATE SECTOR DEVELOPMENT.

Warmup  Why does the dollar on the left have value, while the one on the right does not?

Lecture 4A: The Bioshield Dilemma: Developing New Technologies At an Affordable Price Introduction to Homeland Security Sept. 21, 2005 Stephen M. Maurer.

Economics Chapter 3: Your Role as a Consumer

Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan.

Beyond the Ivory Tower: Making Practical Choices Stephen M. Maurer Goldman School of Public Policy & Berkeley Law School March 16, 2009.

Focusing on the key challenges Decision-making & drug development Peter Hertzman Paul Miller.

Innovation Economics (Pt. 1): “Pull” Mechanisms, Mostly Prizes Stephen M. Maurer Designing Strategies for Neglected Disease Research Law Public.

Where to Find the Course: Home Page: Wiki:

Finding Cures for Tropical Diseases: Choosing the Right Incentives Stephen M. Maurer Goldman School of Public Policy, UC Berkeley May 23, 2007 European.

1 An Introduction to IP Law and Economics Stephen M. Maurer Goldman School of Public Policy IT and Public Policy – Sept. 30, 2004.

The Framework for business.

SUCCESS FACTORS IN THE PHARMACEUTICAL MARKETPLACE

The Global Pharmaceutical Industry Timothy F Christian, MD, MPA.

Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,

1 New Funding Model Key features and implementation Inter-Agency Meeting 5-7 March 2014 Linda Mafu, Head Political and Civil Society Advocacy Department,

1 Global New Employee Orientation Workshop Welcome.

1 Chapter 1: What is Finance? Copyright © Prentice Hall Inc Author: Nick Bagley, bdellaSoft, Inc. Objective To Define Finance The Value of Finance.

Privatization in Asia by Dr. Klaus-Peter Kriegsmann Bali, 11 May 2000.

Innovation Economics (Pt. 2): “Push” Mechanisms, Mostly Private-Public Partnerships Private-Public Partnerships Stephen M. Maurer Designing Strategies.

STRATEGIC MANAGEMENT 1 Irina Raynaud Pierre Jean Tessier Nicolas Cabrit Clément Tumoine.

WARMUP  Why does the dollar on the left have value, while the one on the right does not?

By: 1. Kenneth A. Kim John R. Nofsinger And 2. A. C. Fernando.

WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.

Todd Hamilton District Sales Manager. Innovation  On average it takes scientists, physicians, engineers, and other researchers between 10 and 15 years.

1 MIAG 2 Response to Industry -Emerging markets Eva M A Ombaka.

REACHING GLOBAL MARKETS C HAPTER. Marketing that targets customers throughout the world. More customers=more money. Good thing, right? Global Marketing.

John M. Simpson Stem Cell Project Director Foundation for Taxpayer and Consumer Rights Tel: URL:

Incentives for Innovation (Push and Pull) Andrew Alexandra Director Australian Research Council Special Research Centre for Applied Philosophy and Public.

Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“

Can Competition-Promoting Policies Reduce Medicine Prices in Developing Countries? Loraine Hawkins ICIUM, Track 2c Economics Tuesday, 15 November,

 Trade between two or more countries is called foreign trade or international trade. This involves the exchange of goods and services between the citizens.

HSC 6636: Pharmaceuticals & Medical Technology 1 Dr. Lawrence West, Health Management and Informatics Department, University of Central Florida

THE FUTURE OF THE DEVELOPMENTAL STATE In Africa PIA 2574.

Firms make acquisitions to create value for shareholders Reasons often cited for making acquisitions – improve the performance of the company – consolidate.

Strong Medicine: Designing Pharmaceutical Markets to Treat Neglected Diseases Michael Kremer May 9, 2008 Harvard University, Brookings Institution, Center.

Wiener Institut für Internationale Wirtschaftsvergleiche The Vienna Institute for International Economic Studies FDI in SEE countries by.

Free Enterprise.

Patents, Prizes, AMCs and CAMCs Aidan Hollis University of Calgary October 2007.

D. Marketing a Small Business 6.00 Explain the fundamentals of marketing in a small business Explain marketing and its importance.

Environmental Policy. Who Killed the Electric Car? Consumers Oil companies Auto manufactures Government.

The Pilot Advance Market Commitment for Vaccines Tania Cernuschi Senior Manager, AMC GAVI Alliance Marketplace on Innovative.

Issues related to poor IP protection in EMs: Pharmaceutical Example Rob May Commercial Director, Janssen, EMEA Emerging Markets.

Sources of Capital for Start Ups Frank Demmler Associate Teaching Professor of Entrepreneurship Donald H. Jones Center for Entrepreneurship Tepper School.

1 Medication Development for Treatment of Drug Dependence Donald R. Wesson, MD Consultant, CNS Medications Development Chairman, ASAM Medications Development.

Mariana Mazzucato (2015) Building the Entrepreneurial State Author of The Entrepreneurial State. Debunking the Public vs. Private Myth in Risk and Innovation.

ARRRR! Drug Development and Discovery Access to Essential Medicines De-Cal Fall Week 2.

D. Marketing a Small Business 6.00 Explain the fundamentals of marketing in a small business Explain marketing and its importance.

MARKETING. What do marketers do? Match the two columns identify anticipate create develop persuade modify design research a product a consumer need a.

Marketing 4 Global Marketing. 4.1 Developing a Global Vision - 4 Importance of global marketing Importance of global marketing Impact of multinational.

D. Marketing a Small Business 6.00 Explain the fundamentals of marketing in a small business Explain marketing and its importance.

httpwww.youtube.com/watch?v=DhxD6sVQEYc:// The Drug Discovery Process.

Welfare Analysis of Parallel Trade Freedom 1/16 An Analysis of the Welfare Effects of Parallel Trade Freedom Frank Müller-Langer International Max Planck.

Vaccine Development, Innovations and Investments Oslo Malaria Conference, “Getting To Zero” Jean Stéphenne, Chairman and President GlaxoSmithKline Biologicals.

D. Marketing a Small Business

ECON 330 Lecture 11 Tuesday, October 30.

EXAMPLE 2-1 Fixed and Variable Costs

The Academic/Industrial

Intellectual Property Protection and Access to Medicines

Overview of Market Participants and Financial Innovation

A journey through drug discovery The life cycle of a new medicine

Free Enterprise.

Accessing Medicines in Africa Prospects and challenges

D. Marketing a Small Business

Inventing Institutions

Group E1 - Improving financing NPP QUESTIONS / DIFFICULTIES

Drug Pricing, Innovation, and the Cycle of Greed

Stage B.Tech. MBA I Proof of Concept Mini Plan & Company Description II Market.

Presentation transcript:

Finding Cures for Tropical Diseases: Putting Innovation Economics to Work Stephen M. Maurer Goldman School of Public Policy Nov. 21, 2006 Economics of Innovation: Econ 124/PP190-4/PP290-4

Theory and Practice Teaching vs. Using

The Problem 500 Million People The Patent System Hasn’t Worked Selling HIV Drugs to Africa

The Opportunity Bill Gates’ Troubles Virtual Pharma AdvancedMarkets Price is Everything!

Basic Concepts Agency Problems – Researchers Agency Problems – Sponsors Eliciting Information Efficient Pricing

The Mantra No Institution is Dominant Pick the Best Institution for The Problem Be Agnostic!

New Wrinkles Efficient Pricing Revisited “Distributional Issues” Multi-Part Innovation Pay-As-You-Go or End-to-End?

The Innovation Environment Basic Research Finding Targets Optimizing Targets Finding Lead Compounds Optimizing Lead Compounds Process Development Pre-Clinical Testing Phase I Tests Phase II Tests Phase III Tests Approval Manufacturing Phase IV Tests Marketing & Distribution

Choices Patent Reform Harmonization & Targeted Interventions Supplementing Patents AdvancedMarkets Replacing Patents Virtual Pharma

Harmonization Depends on Disease TB vs. Malaria vs. Sleeping Sickness Inadequate Reward For Research? For Entering Particular Countries? Parallel Imports

Targeted Grants Virtual Pharma Strategic Investing Crowding Out

AdvancedMarkets Matching Payments Independent Adjudication Committee Why Not a Prize? Hybrid Cases Politics The Patent Mystique Avoiding Choices Hidden Taxes

Is It Efficient? AdvancedMarkets

Picking the Best Institutions AdvancedMarkets

Getting the Best Price AdvancedMarkets

Getting the Best Price (Pt. 2) Estimating the Required Reward R&D Costs The Price of Guessing Wrong AdvancedMarkets

Getting the Best Price (Pt. 3) Estimating R&D Costs The Accounting Answer Drug Company Data Independent Estimates Market Arguments Is the Accounting Answer Right? AdvancedMarkets

Who Gets The Savings? AdvancedMarkets

The Agency Problem AdvancedMarkets

Why An IAC? AdvancedMarkets

Why An IAC? The Corruption Problem AdvancedMarkets

Virtual Pharma Choosing Institutions

Basic Research Finding Targets Optimizing Targets Finding Lead Compounds Optimizing Lead Compounds Process Development Pre-Clinical Testing Phase I Tests Phase II Tests Phase III Tests Approval Manufacturing Phase IV Tests Marketing & Distribution Virtual Pharma: Eliciting Information

Targeted Investment Prizes Grants Contract Research Targeted Tax Credits Government Equity Investments Open Source Harry Fox Licenses Virtual Pharma: Institutions for Eliciting Information

Basic Research Finding Targets Optimizing Targets Finding Lead Compounds Optimizing Lead Compounds Process Development Pre-Clinical Testing Phase I Tests Phase II Tests Phase III Tests Approval Manufacturing Phase IV Tests Marketing & Distribution Virtual Pharma: Agency Problems: Researchers

Targeted Investment Prizes Grants Contract Research Targeted Tax Credits Government Equity Investments Open Source Harry Fox Licenses Virtual Pharma: Institutions & Agency Problems

Virtual Pharma: Efficient Pricing Getting the Best Price The Patent Problem Open Source & Grants Enforcing The Best Price Buying Power & Repeat Games

Virtual Pharma: “Can Government Pick Winners?” Is Pharma Efficient? Shareholders Are Foundations Efficient? Some History Foundations as Shareholders?

Do Hybrids Make Sense? Strategic Investing Picking Winners Splitting the Reward Politics

Choices AdvancedMarkets vs. Virtual Pharma Uncertain R&D Costs Two Stage Competition Big Pharma’s Buying Power Cold-Blooded Foundations

Finding Cures for Tropical Diseases: Putting Innovation Economics to Work Stephen M. Maurer Goldman School of Public Policy Nov. 21, 2006 Economics of Innovation: Econ 124/PP190-4/PP290-4